US5681714A
(en)
*
|
1992-07-30 |
1997-10-28 |
Mount Sinai Hospital Corporation |
Nucleic acid encoding tek receptor tyrosine kinase
|
US6221839B1
(en)
|
1994-11-14 |
2001-04-24 |
Helsinki University Licensing Ltd. Oy |
FIt4 ligand and methods of use
|
US6245530B1
(en)
|
1995-08-01 |
2001-06-12 |
Ludwig Institute For Cancer Research |
Receptor ligand
|
US6645933B1
(en)
|
1995-08-01 |
2003-11-11 |
Helsinki University Licensing Ltd. Oy |
Receptor ligand VEGF-C
|
US6403088B1
(en)
|
1995-08-01 |
2002-06-11 |
Helsinki University Licensing, Ltd. |
Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
|
US6130071A
(en)
*
|
1997-02-05 |
2000-10-10 |
Helsinki University Licensing, Ltd. |
Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof
|
US6818220B1
(en)
|
1994-11-14 |
2004-11-16 |
Licentia Ltd. |
Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
|
DE69633121T2
(de)
|
1995-04-06 |
2005-07-28 |
Regeneron Pharmaceuticals, Inc. |
Tie-2 liganden, herstellungsverfahren und verwendung
|
AU755337B2
(en)
*
|
1995-04-06 |
2002-12-12 |
Regeneron Pharmaceuticals, Inc. |
New uses of tie-2 ligands
|
US7727761B2
(en)
|
1995-08-01 |
2010-06-01 |
Vegenics Limited |
Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
|
US6361946B1
(en)
|
1997-02-05 |
2002-03-26 |
Licentia Ltd |
Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
|
DE69638142D1
(de)
|
1995-09-29 |
2010-04-15 |
Univ Siena |
Regulierte Gene und ihre Verwendungen
|
US7063965B2
(en)
*
|
1996-04-05 |
2006-06-20 |
Regeneron Pharmaceuticals, Inc. |
Nucleic acid encoding TIE-2 ligand
|
DE19623850A1
(de)
*
|
1996-06-14 |
1997-12-18 |
Wacker Chemie Gmbh |
Homogenisierung von Dispersionen
|
JP2000513932A
(ja)
|
1996-06-19 |
2000-10-24 |
リジェネロン ファーマシューティカルズ,インコーポレイテッド |
Tie―2レセプターリガンド(tieリガンド―3;tieリガンド―4)およびそれらの使用
|
US6846914B2
(en)
|
1996-06-19 |
2005-01-25 |
Regeneron Pharmaceuticals, Inc. |
Tie-2 ligand-3
|
US5851797A
(en)
*
|
1996-06-19 |
1998-12-22 |
Regeneron Pharmaceuticals, Inc. |
Tie ligand-3, methods of making and uses thereof
|
US6265564B1
(en)
*
|
1996-08-02 |
2001-07-24 |
Regeneron Pharmaceuticals, Inc. |
Expressed ligand-vascular intercellular signalling molecule
|
DE69739469D1
(de)
|
1996-08-23 |
2009-07-30 |
Vegenics Ltd |
Rekombinanter vasculärer Endothelzellen Wachstumsfaktor D (VEGF-D)
|
US7125714B2
(en)
|
1997-02-05 |
2006-10-24 |
Licentia Ltd. |
Progenitor cell materials and methods
|
US6350450B1
(en)
|
1997-09-19 |
2002-02-26 |
Genentech, Inc. |
TIE ligand homologue antibody
|
US5972338A
(en)
|
1997-09-19 |
1999-10-26 |
Genentech, Inc. |
Tie ligands homologues
|
US6057435A
(en)
|
1997-09-19 |
2000-05-02 |
Genentech, Inc. |
Tie ligand homologues
|
US6030831A
(en)
*
|
1997-09-19 |
2000-02-29 |
Genetech, Inc. |
Tie ligand homologues
|
US6348350B1
(en)
|
1997-09-19 |
2002-02-19 |
Genentech, Inc. |
Ligand homologues
|
AU2000399A
(en)
*
|
1997-12-19 |
1999-07-12 |
Regeneron Pharmaceuticals, Inc. |
Receptor tyrosine kinase, ar-1, is a regulator of angiogenesis
|
WO1999032515A2
(en)
*
|
1997-12-19 |
1999-07-01 |
Zymogenetics, Inc. |
Angiopoietin homolog, dna encoding it, and method of making it
|
WO1999040193A1
(en)
*
|
1998-02-04 |
1999-08-12 |
Zymogenetics, Inc. |
Angiopoietin homolog zapo3, dna encoding it, and method of making it
|
EP1058737A4
(en)
*
|
1998-03-02 |
2003-01-02 |
Millennium Pharm Inc |
FDRG PROTEIN AND NUCLEIC ACID MOLECULES AND THEIR USE
|
EP1060261B1
(en)
|
1998-03-02 |
2010-05-05 |
Massachusetts Institute of Technology |
Poly zinc finger proteins with improved linkers
|
US7488590B2
(en)
*
|
1998-10-23 |
2009-02-10 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
US6706687B1
(en)
|
1998-11-10 |
2004-03-16 |
Ludwig Institute For Cancer Research |
Platelet-derived growth factor D
|
EP1141294B1
(en)
|
1998-12-23 |
2005-03-02 |
Regeneron Pharmaceuticals, Inc. |
Method of enhancing the biological activity of ligands
|
JP2002537813A
(ja)
*
|
1999-03-02 |
2002-11-12 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
アンギオポエチンに関連しているタンパク質および核酸
|
US6455035B1
(en)
|
1999-03-26 |
2002-09-24 |
Regeneron Pharmaceuticals, Inc. |
Angiopoietins and methods of use thereof
|
US6703020B1
(en)
|
1999-04-28 |
2004-03-09 |
Board Of Regents, The University Of Texas System |
Antibody conjugate methods for selectively inhibiting VEGF
|
KR100816572B1
(ko)
|
1999-04-28 |
2008-03-24 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
항-vegf 항체 및 이를 포함하는 약제학적 조성물
|
DK1187918T4
(da)
*
|
1999-06-07 |
2009-02-23 |
Immunex Corp |
TEK-antagonister
|
US6521424B2
(en)
|
1999-06-07 |
2003-02-18 |
Immunex Corporation |
Recombinant expression of Tek antagonists
|
EP1953173B1
(en)
|
1999-06-15 |
2009-11-18 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids endoding the same
|
US6689035B1
(en)
|
2000-04-11 |
2004-02-10 |
Gerber Scientific Products, Inc. |
Method and apparatus for designing and creating a package
|
JP2004537260A
(ja)
|
2000-12-07 |
2004-12-16 |
サンガモ バイオサイエンシーズ, インコーポレイテッド |
ジンクフィンガータンパク質による血管新生の調節
|
US7067317B2
(en)
|
2000-12-07 |
2006-06-27 |
Sangamo Biosciences, Inc. |
Regulation of angiogenesis with zinc finger proteins
|
US7658924B2
(en)
*
|
2001-10-11 |
2010-02-09 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
US7138370B2
(en)
*
|
2001-10-11 |
2006-11-21 |
Amgen Inc. |
Specific binding agents of human angiopoietin-2
|
US7521053B2
(en)
*
|
2001-10-11 |
2009-04-21 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
AU2006228095B2
(en)
*
|
2001-10-11 |
2010-11-04 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
US7205275B2
(en)
*
|
2001-10-11 |
2007-04-17 |
Amgen Inc. |
Methods of treatment using specific binding agents of human angiopoietin-2
|
US20050123925A1
(en)
|
2002-11-15 |
2005-06-09 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
WO2003034990A2
(en)
|
2001-10-25 |
2003-05-01 |
Regeneron Pharmaceuticals, Inc. |
Angiopoietins and methods of use thereof
|
JP4242590B2
(ja)
|
2002-01-11 |
2009-03-25 |
俊一 塩澤 |
慢性関節リウマチの疾患感受性遺伝子、及びその利用
|
US7427594B1
(en)
*
|
2002-02-26 |
2008-09-23 |
The Trustees Of The University Of Pennsylvania |
Methods and pharmaceuticals compositions for treating coronary artery disease, ischemia,and vascular disease using angiopoietins
|
US7081443B2
(en)
|
2002-05-21 |
2006-07-25 |
Korea Advanced Institutes Of Science And Technology (Kaist) |
Chimeric comp-ang1 molecule
|
US20040115640A1
(en)
*
|
2002-12-11 |
2004-06-17 |
Isis Pharmaceuticals Inc. |
Modulation of angiopoietin-2 expression
|
CN1684706A
(zh)
|
2002-07-23 |
2005-10-19 |
路德维格癌症研究所 |
活化或抑制vegf-d和vegf-c的方法和组合物
|
AU2003297282A1
(en)
|
2002-11-14 |
2004-06-15 |
Cornell Research Foundation, Inc. |
Protection of cardiac myocardium
|
MEP31408A
(en)
|
2003-07-18 |
2010-10-10 |
Abgenix Inc |
Specific binding agents to hepatocyte growth factor
|
CN1323723C
(zh)
*
|
2003-12-26 |
2007-07-04 |
上海新世界基因技术开发有限公司 |
Tie2受体介导的靶向性肿瘤基因治疗的基因转移系统
|
US8298532B2
(en)
|
2004-01-16 |
2012-10-30 |
Regeneron Pharmaceuticals, Inc. |
Fusion polypeptides capable of activating receptors
|
US20060024302A1
(en)
|
2004-03-05 |
2006-02-02 |
Ludwig Institute For Cancer Research |
Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same
|
US8604185B2
(en)
|
2004-07-20 |
2013-12-10 |
Genentech, Inc. |
Inhibitors of angiopoietin-like 4 protein, combinations, and their use
|
NZ552956A
(en)
|
2004-07-20 |
2010-03-26 |
Genentech Inc |
Inhibitors of angiopoietin-like 4 protein (ANGPTL4), combinations, and their use for treating cancer
|
CA2595610C
(en)
|
2004-12-21 |
2013-03-05 |
Astrazeneca Ab |
Antibodies directed to angiopoietin-2 and uses thereof
|
US8114884B2
(en)
*
|
2005-01-07 |
2012-02-14 |
Emory University |
CXCR4 antagonists for the treatment of medical disorders
|
JP4657757B2
(ja)
*
|
2005-02-23 |
2011-03-23 |
株式会社膠原病研究所 |
肺高血圧症発症関連遺伝子を用いた肺高血圧症の診断および治療
|
JP2006325528A
(ja)
*
|
2005-05-27 |
2006-12-07 |
Institute For Rheumatic Diseases Co Ltd |
糖尿病性網膜症の診断および予防
|
JP4657857B2
(ja)
*
|
2005-08-25 |
2011-03-23 |
株式会社膠原病研究所 |
メタボリックシンドロームの診断および予防
|
NZ569787A
(en)
*
|
2005-12-15 |
2011-07-29 |
Astrazeneca Ab |
Combination of angiopoietin-2 antagonist and of VEGF-A, KDR and/or FLT1 antagonist for treating cancer
|
AR059066A1
(es)
*
|
2006-01-27 |
2008-03-12 |
Amgen Inc |
Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
|
BRPI0711358A2
(pt)
|
2006-05-09 |
2011-09-27 |
Pfizer Prod Inc |
derivados do ácido cicloalquilamino e suas composições farmacêuticas
|
ES2650224T3
(es)
|
2007-08-21 |
2018-01-17 |
Amgen, Inc. |
Proteínas de unión al antígeno C-FMS humano
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
US8227577B2
(en)
*
|
2007-12-21 |
2012-07-24 |
Hoffman-La Roche Inc. |
Bivalent, bispecific antibodies
|
US8454960B2
(en)
|
2008-01-03 |
2013-06-04 |
The Scripps Research Institute |
Multispecific antibody targeting and multivalency through modular recognition domains
|
US8557243B2
(en)
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
EFGR antibodies comprising modular recognition domains
|
US8574577B2
(en)
|
2008-01-03 |
2013-11-05 |
The Scripps Research Institute |
VEGF antibodies comprising modular recognition domains
|
US8557242B2
(en)
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
ERBB2 antibodies comprising modular recognition domains
|
NZ586701A
(en)
|
2008-01-03 |
2013-07-26 |
Scripps Research Inst |
Antibody targeting through a modular recognition domain (MRD) wherein the MRD targets angiopoietin-2 (ANG-2)
|
US8507656B2
(en)
|
2008-01-28 |
2013-08-13 |
Medimmune Limited |
Stabilized angiopoietin-2 antibodies and uses thereof
|
JO2913B1
(en)
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
|
AU2009262199B2
(en)
|
2008-06-27 |
2012-08-09 |
Amgen Inc. |
Ang-2 inhibition to treat multiple sclerosis
|
US8268314B2
(en)
|
2008-10-08 |
2012-09-18 |
Hoffmann-La Roche Inc. |
Bispecific anti-VEGF/anti-ANG-2 antibodies
|
US8133979B2
(en)
|
2008-12-16 |
2012-03-13 |
Hoffmann-La Roche Inc. |
Antibodies against human angiopoietin 2
|
CN102369215B
(zh)
*
|
2009-04-02 |
2015-01-21 |
罗切格利卡特公司 |
包含全长抗体和单链Fab片段的多特异性抗体
|
PT2417156E
(pt)
|
2009-04-07 |
2015-04-29 |
Roche Glycart Ag |
Anticorpos trivalentes, biespecíficos
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
US8980268B2
(en)
|
2009-07-29 |
2015-03-17 |
Regeneron Pharamceuticals, Inc. |
Methods for treating cancer by administering an anti-Ang-2 antibody
|
JO3182B1
(ar)
*
|
2009-07-29 |
2018-03-08 |
Regeneron Pharma |
مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
|
US20120189635A1
(en)
|
2009-07-29 |
2012-07-26 |
Regeneron Pharmaceuticals, Inc. |
Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2)
|
US20120302737A1
(en)
|
2009-09-16 |
2012-11-29 |
Genentech, Inc. |
Coiled coil and/or tether containing protein complexes and uses thereof
|
US20120183546A1
(en)
|
2009-09-23 |
2012-07-19 |
Amgen Inc. |
Treatment of ovarian cancer using a specific binding agent of human angiopoietin-2 in combination with a taxane
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
TWI426920B
(zh)
|
2010-03-26 |
2014-02-21 |
Hoffmann La Roche |
雙專一性、雙價抗-vegf/抗-ang-2抗體
|
US20120100166A1
(en)
|
2010-07-15 |
2012-04-26 |
Zyngenia, Inc. |
Ang-2 Binding Complexes and Uses Thereof
|
BR112013001847A2
(pt)
|
2010-08-24 |
2016-05-31 |
Hoffmann La Roche |
anticorpo biespecífico, método de preparação do anticorpo biespecífico, do anticorpo biespecífico trivalente, métodos e composição farmacêutica
|
SG191153A1
(en)
|
2010-12-23 |
2013-07-31 |
Hoffmann La Roche |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
KR101572338B1
(ko)
|
2011-02-28 |
2015-11-26 |
에프. 호프만-라 로슈 아게 |
1가 항원 결합 단백질
|
WO2012116926A1
(en)
|
2011-02-28 |
2012-09-07 |
F. Hoffmann-La Roche Ag |
Antigen binding proteins
|
CN103857699B
(zh)
|
2011-05-24 |
2016-08-31 |
泽恩格尼亚股份有限公司 |
多价和单价多特异性复合物及其用途
|
EP2726088B1
(en)
|
2011-06-29 |
2019-01-02 |
Amgen Inc. |
Predictive biomarker of survival in the treatment of renal cell carcinoma
|
NZ627859A
(en)
|
2012-01-23 |
2015-09-25 |
Regeneron Pharma |
Stabilized formulations containing anti-ang2 antibodies
|
JP6486686B2
(ja)
|
2012-02-10 |
2019-03-20 |
ジェネンテック, インコーポレイテッド |
単鎖抗体及び他のヘテロ多量体
|
WO2013134516A1
(en)
|
2012-03-08 |
2013-09-12 |
Medimmune, Llc |
Methods of treatment with angiopoietin-2 antibodies
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
AU2013241769B2
(en)
|
2012-03-30 |
2017-05-11 |
Boehringer Ingelheim International Gmbh |
Ang2-binding molecules
|
RU2639287C2
(ru)
|
2012-06-27 |
2017-12-20 |
Ф. Хоффманн-Ля Рош Аг |
Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
|
WO2014001325A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
|
EP3495387B1
(en)
|
2012-07-13 |
2021-09-01 |
Roche Glycart AG |
Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
|
WO2014108854A1
(en)
|
2013-01-09 |
2014-07-17 |
Fusimab Ltd. |
Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies
|
EP3424530A1
(en)
|
2013-03-15 |
2019-01-09 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
CA2922912A1
(en)
|
2013-10-11 |
2015-04-16 |
F. Hoffmann-La Roche Ag |
Multispecific domain exchanged common variable light chain antibodies
|
AU2014407088B2
(en)
|
2014-09-26 |
2021-09-23 |
Somalogic Operating Co., Inc. |
Cardiovascular risk event prediction and uses thereof
|
JP2017532342A
(ja)
|
2014-10-17 |
2017-11-02 |
アムジエン・インコーポレーテツド |
眼療法のためのアンジオポエチン−1及びアンジオポエチン−2を対象とする抗体
|
ES2764111T3
(es)
|
2014-12-03 |
2020-06-02 |
Hoffmann La Roche |
Anticuerpos multiespecíficos
|
WO2016209972A1
(en)
|
2015-06-26 |
2016-12-29 |
Amgen Inc. |
Biomarker of survival in the treatment of renal cell carcinoma with a vegfr inhibitor and an ang2 inhibitor
|
AU2016369557B2
(en)
|
2015-12-16 |
2022-10-20 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods of manufacturing protein microparticles
|
KR102543878B1
(ko)
|
2016-08-23 |
2023-06-14 |
메디뮨 리미티드 |
항-vegf-a 및 항-ang2 항체 및 이의 용도
|
CA3233933A1
(en)
|
2017-01-30 |
2018-08-02 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for reducing bioburden in chromatography
|
CA3185107A1
(en)
|
2017-10-12 |
2019-04-18 |
Immunowake Inc. |
Vegfr-antibody light chain fusion protein
|